Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

NVIDIA Ignites the Next Industrial Revolution in Knowledge Work With Open Agent Development Platform

View original at finance.yahoo.com
NVIDIA Ignites the Next Industrial Revolution in Knowledge Work With Open Agent Development Platform NVIDIA NVIDIA Agent Toolkit Equips Enterprises to Build and Run AI Agents NVIDIA Agent ToolkitNVIDIA Agent Toolkit and NVIDIA OpenShell open source runtime ignite the next era of AI with open source software for autonom…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Claude Code and OpenClaw have sparked the agent inflection point, extending AI beyond generation and reasoning into action

    60% confidence
  • The IT industry is on the brink of its next great expansion

    60% confidence
  • Employees will be supercharged by teams of frontier, specialized and custom-built agents they deploy and manage

    60% confidence
  • The enterprise software industry will evolve into specialized agentic platforms

    60% confidence
  • The AI-Q hybrid architecture can cut query costs by more than 50% while providing world-class accuracy

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
NVIDIA Ignites the Next Industrial Revolution in Knowledge Work With Open Agent Development Platform — Source | Via News | ViaNews Market